G1 Therapeutics (GTHX) PT Raised to $76 at Needham & Company as Protocol Amendment

Needham & Company analyst Chad Messer raised the price target on G1 Therapeutics (NASDAQ: GTHX) to $76.00 (from $60.00) while maintaining a Buy rating.

Messer commented, "G1 is amending the protocol for its Phase II trial testing trilaciclib in combination with chemotherapy and Tecentriq. The primary endpoint will now be myelopreservation and that data will be available in 4Q. OS data (former primary) will still readout as planned in 2019/20. We believe the myelopreservation data from this trial may help bolster the available dataset G1 intends to bring to the FDA in 1H:19 to discuss a path to approval. We next look for updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October. Additional updates in 4Q, in addition to the myelopreservation data from the Tecentriq trial, include 2nd/3rd line SCLC and TNBC data for trilaciclib in 4Q. We reiterate out Buy rating on GTHX and are increasing our price target to $76 as we head into an important data rich 4Q. "

You May Also Be Interested In

• Oncolytics Biotech (ONCY) PT Lowered to $5 at H.C. Wainwright
• BMO Capital Starts Ascendis Pharma (ASND) at Outperform
• BMO Capital Starts Perspective Therapeutics Inc (CATX) at Outperform